Marty Jean-Paul L, Lambert Julien, Jäckel Andreas, Adjadj Lucie
Unité de Recherche en Dermopharmacologie et Cosmétologie, Faculté de Pharmacie, Université Paris Sud, 92296 Châtenay Malabry, France.
J Dermatolog Treat. 2005;16(5-6):299-307. doi: 10.1080/09546630500375965.
To assess the daily treatment costs and the average cost-effectiveness of three topical onychomycosis therapies - amorolfine 5% and ciclopirox 8% nail lacquers and tioconazole 28% nail solution - when used as indicated in France, the UK, Germany and Italy.
The quantity of drug required and nail size measurements were investigated and, knowing the cost per bottle of each study drug, used to calculate the average treatment cost per patient. Using the prevalence of infection data, the weighted average total treatment cost per patient and hence the weighted average daily treatment cost and cost per patient cured, were calculated.
Amorolfine was consistently more cost-effective in terms of weighted average daily treatment cost and cost per patient cured than ciclopirox and tioconazole, when all therapies were used as indicated to treat onychomycosis. In France, for example, the weighted average daily treatment cost of amorolfine was found to be euro 0.23 and euro 0.40 when used once and twice a week, respectively; the cost per patient cured for amorolfine was euro 84. By comparison, the weighted average daily treatment cost of ciclopirox was found to be euro 0.81; the cost per patient cured was euro 252.
When used as indicated, amorolfine 5% nail lacquer is more cost-effective than ciclopirox 8% and tioconazole 28% for onychomycosis of toenail, fingernail or both in males and females in France, UK, Germany and Italy.
评估三种外用甲真菌病治疗药物——5%阿莫罗芬、8%环吡酮甲涂剂和28%联苯苄唑甲溶液——在法国、英国、德国和意大利按说明使用时的每日治疗成本和平均成本效益。
研究所需药物量和指甲尺寸测量值，并根据每种研究药物每瓶的成本，计算每位患者的平均治疗成本。利用感染患病率数据，计算每位患者的加权平均总治疗成本，进而得出加权平均每日治疗成本和每位治愈患者的成本。
当所有疗法均按说明用于治疗甲真菌病时，就加权平均每日治疗成本和每位治愈患者的成本而言，阿莫罗芬始终比环吡酮和联苯苄唑更具成本效益。例如，在法国，阿莫罗芬每周使用一次和两次时，加权平均每日治疗成本分别为0.23欧元和0.40欧元；阿莫罗芬每位治愈患者的成本为84欧元。相比之下，环吡酮的加权平均每日治疗成本为0.81欧元；每位治愈患者的成本为252欧元。
在法国、英国、德国和意大利，对于男性和女性的趾甲、指甲或两者的甲真菌病，按说明使用时，5%阿莫罗芬甲涂剂比8%环吡酮和28%联苯苄唑更具成本效益。
